請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/81648完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李財坤(Tsai-Kun Li) | |
| dc.contributor.author | Deng-Yu Jiang | en |
| dc.contributor.author | 姜鐙淯 | zh_TW |
| dc.date.accessioned | 2022-11-24T09:25:12Z | - |
| dc.date.copyright | 2021-08-19 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-07-26 | |
| dc.identifier.citation | Aragón, I. M., Herrera-Imbroda, B., Queipo-Ortuño, M. I., Castillo, E., Del Moral, J. S., Gómez-Millán, J., . . . Lara, M. F. (2018). The Urinary Tract Microbiome in Health and Disease. Eur Urol Focus, 4(1), 128-138. doi:10.1016/j.euf.2016.11.001 Boleij, A., Hechenbleikner, E. M., Goodwin, A. C., Badani, R., Stein, E. M., Lazarev, M. G., . . . Sears, C. L. (2015). The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis, 60(2), 208-215. doi:10.1093/cid/ciu787 Cheng, W. Y., Wu, C. Y., Yu, J. (2020). The role of gut microbiota in cancer treatment: friend or foe? Gut, 69(10), 1867-1876. doi:10.1136/gutjnl-2020-321153 Chiu, P. K., Ng, C. F., Semjonow, A., Zhu, Y., Vincendeau, S., Houlgatte, A., . . . Roobol, M. J. (2019). A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol, 75(4), 558-561. doi:10.1016/j.eururo.2018.10.047 Chong, J., Liu, P., Zhou, G., Xia, J. (2020). Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome data. Nat Protoc, 15(3), 799-821. doi:10.1038/s41596-019-0264-1 Culp, M. B., Soerjomataram, I., Efstathiou, J. A., Bray, F., Jemal, A. (2020). Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol, 77(1), 38-52. doi:10.1016/j.eururo.2019.08.005 de Bono, J. S., Guo, C., Gurel, B., De Marzo, A. M., Sfanos, K. S., Mani, R. S., . . . Alimonti, A. (2020). Prostate carcinogenesis: inflammatory storms. Nature Reviews Cancer, 20(8), 455-469. doi:10.1038/s41568-020-0267-9 De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., . . . Nelson, W. G. (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer, 7(4), 256-269. doi:10.1038/nrc2090 Faith, J. J., Guruge, J. L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A. L., . . . Gordon, J. I. (2013). The long-term stability of the human gut microbiota. Science, 341(6141), 1237439. doi:10.1126/science.1237439 Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., Wargo, J. A. (2018). The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell, 33(4), 570-580. doi:10.1016/j.ccell.2018.03.015 Hilt, E. E., McKinley, K., Pearce, M. M., Rosenfeld, A. B., Zilliox, M. J., Mueller, E. R., . . . Schreckenberger, P. C. (2014). Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol, 52(3), 871-876. doi:10.1128/jcm.02876-13 Hong, B.-y., Ideta, T., Lemos, B. S., Igarashi, Y., Tan, Y., DiSiena, M., . . . Rosenberg, D. W. (2019). Characterization of Mucosal Dysbiosis of Early Colonic Neoplasia. npj Precision Oncology, 3(1), 29. doi:10.1038/s41698-019-0101-6 Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., . . . The Human Microbiome Project, C. (2012). Structure, function and diversity of the healthy human microbiome. Nature, 486(7402), 207-214. doi:10.1038/nature11234 International Human Genome Sequencing, C. (2004). Finishing the euchromatic sequence of the human genome. Nature, 431(7011), 931-945. doi:10.1038/nature03001 Ma, X., Chi, C., Fan, L., Dong, B., Shao, X., Xie, S., . . . Xue, W. (2019). The Microbiome of Prostate Fluid Is Associated With Prostate Cancer. Front Microbiol, 10, 1664. doi:10.3389/fmicb.2019.01664 Metwaly, A., Dunkel, A., Waldschmitt, N., Raj, A. C. D., Lagkouvardos, I., Corraliza, A. M., . . . Haller, D. (2020). Integrated microbiota and metabolite profiles link Crohn’s disease to sulfur metabolism. Nature Communications, 11(1), 4322. doi:10.1038/s41467-020-17956-1 Mueller, E. R., Wolfe, A. J., Brubaker, L. (2017). Female urinary microbiota. Current opinion in urology, 27(3), 282-286. doi:10.1097/MOU.0000000000000396 Oh, D., Cheon, K.-A. (2020). Alteration of Gut Microbiota in Autism Spectrum Disorder: An Overview. Soa--ch'ongsonyon chongsin uihak = Journal of child adolescent psychiatry, 31(3), 131-145. doi:10.5765/jkacap.190039 Pope, J. L., Tomkovich, S., Yang, Y., Jobin, C. (2017). Microbiota as a mediator of cancer progression and therapy. Translational research : the journal of laboratory and clinical medicine, 179, 139-154. doi:10.1016/j.trsl.2016.07.021 Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., . . . Glöckner, F. O. (2013). The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic acids research, 41(Database issue), D590-D596. doi:10.1093/nar/gks1219 Ruan, J. W., Statt, S., Huang, C. T., Tsai, Y. T., Kuo, C. C., Chan, H. L., . . . Kao, C. Y. (2016). Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice. Nat Microbiol, 2, 16220. doi:10.1038/nmicrobiol.2016.220 Scales, B. S., Dickson, R. P., LiPuma, J. J., Huffnagle, G. B. (2014). Microbiology, genomics, and clinical significance of the Pseudomonas fluorescens species complex, an unappreciated colonizer of humans. Clinical microbiology reviews, 27(4), 927-948. doi:10.1128/CMR.00044-14 Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., Huttenhower, C. (2011). Metagenomic biomarker discovery and explanation. Genome Biol, 12(6), R60. doi:10.1186/gb-2011-12-6-r60 Shrestha, E., White, J. R., Yu, S. H., Kulac, I., Ertunc, O., De Marzo, A. M., . . . Sfanos, K. S. (2018). Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol, 199(1), 161-171. doi:10.1016/j.juro.2017.08.001 Siegel, R. L., Miller, K. D., Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7-30. doi:https://doi.org/10.3322/caac.21590 Souto, R., Silva-Boghossian, C. M., Colombo, A. P. (2014). Prevalence of Pseudomonas aeruginosa and Acinetobacter spp. in subgingival biofilm and saliva of subjects with chronic periodontal infection. Braz J Microbiol, 45(2), 495-501. doi:10.1590/s1517-83822014000200017 Tulstrup, M. V.-L., Christensen, E. G., Carvalho, V., Linninge, C., Ahrné, S., Højberg, O., . . . Bahl, M. I. (2015). Antibiotic Treatment Affects Intestinal Permeability and Gut Microbial Composition in Wistar Rats Dependent on Antibiotic Class. PloS one, 10(12), e0144854-e0144854. doi:10.1371/journal.pone.0144854 Whiteside, S. A., Razvi, H., Dave, S., Reid, G., Burton, J. P. (2015). The microbiome of the urinary tract--a role beyond infection. Nat Rev Urol, 12(2), 81-90. doi:10.1038/nrurol.2014.361 Wong, S. H., Yu, J. (2019). Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nature Reviews Gastroenterology Hepatology, 16(11), 690-704. doi:10.1038/s41575-019-0209-8 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/81648 | - |
| dc.description.abstract | "儘管目前臨床上治療方法取得了巨大進步，參雜了各種複雜遺傳因素的癌症依然是全球最主要的致死原因之一。近年來，微生物被認為在健康轉向疾病狀態的過程（例如肥胖和癌症）以及治療效果等方面發揮著關鍵作用。分析功能性益生菌在胃腸道中之潛在影響的研究也顯示了在減輕不良反應抑或是提高治療效果方面有著良好的益處。我們的實驗室先前已經建立了女性泌尿生殖系統(GU tract)微生物群的分析平台，並發現女性生殖泌尿道之微生物群與生殖健康和致病微生物之間存在高度相關性。我們利用現有的技術，在此著重於男性生殖泌尿道微生物群與前列腺健康、前列腺癌(PCa)進展和治療應用之間的潛在關聯。為了達成目標，我們將接受根治性前列腺切除術的前列腺癌(PCa)患者的尿液樣本定義為主要的研究對象，以通過 16S rDNA 定序和培養體學分析檢測當中的微生物群。本研究招募了不同的患者，包括前列腺切除術患者和主動監測患者(AS)。首先將獲得的定序數據與癌症分期或各種臨床參數進行比較。在這項縱向研究 (n = 112) 中，我們對尿液微生物群進行了分析，發現到不同風險分類的PCa 患者表現出不同的微生物群組成。值得注意的是，Carnobacterium spp.和Pseudomonas fluorescens是中度危險患者族群中的兩個主要微生物標誌物。此外，許多潛在的微生物標誌物也顯示出與前列腺癌進展的正相關或負相關：（i）我們觀察到Firmicutes菌門和Pseudomonas菌屬在中高風險患者中均佔有優勢；(ii) 相反，Proteobacteria, Actinobacteria菌門和Staphylococcus菌屬在 AS 患者(低風險)中則具有相對較高的豐富度；(iii) 同時我們還發現接受前列腺切除術後患者尿液中Staphylococcus菌屬的相對豐度提高；(iv) 而Streptococcus and Corynebacterium菌屬在接受前列腺切除術前的患者尿液中則具有更高的富集。另外，我們還成功地從我們的臨床樣本中培養、鑑定和保存了幾種細菌菌株，例如Finegoldia magna 和Streptococcus菌屬。在本篇研究中，我們探討了男性生殖泌尿道微生物群之組成與生殖泌尿道健康的關係。我們的結果表明，男性生殖泌尿道中的細菌不僅可能與前列腺癌的進程具有病理或生理學上的相關性，並且具有可作為與癌症風險分期相對應的生物標誌物的巨大潛力。" | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-24T09:25:12Z (GMT). No. of bitstreams: 1 U0001-2607202100065600.pdf: 4696466 bytes, checksum: 50f96842b134b22ae728028a59fd48f2 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | "致謝 ……….………….………….………….…………….………………...………..…I 中文摘要 ……….………….………….………………….………….……….…….…..II ABSTRACT ……….………….………….………….…….…….……….……………IV CONTENT ..……….………….………….………….…….……..…….…………...…VI INTRODUCTION ……….………….………….………….………….………….……1 1. Prostate Cancer ……….…………..………….………….……….…….………….…1 1.1 Prostate Inflammation: Microbial Stress ……….………….…………….………1 2. Human Microbiome ……….………….………….………………………….………2 2.1 Genitourinary Tract Microbiome ……….….………….……………...……….…4 3. Prostate Cancer Diagnosis ……….………….………….…….………..………….…5 3.1 Prostate Specific Antigen test ……….………….………….………………….…5 3.2 Prostate Health Index ……….………….………….………….………….……...6 SPECIFIC AIMS ……….………….………….………….………….…………………8 MATERIALS AND METHODS …….………….………….………….…...……….…9 1. Study Cohort ……….………….……….……….……….……….….…...……….…9 2. Sample Collection and Processing .……….……….………….……….……….……9 3. DNA Extraction and Bacterial 16S Ribosomal rDNA Sequencing .……….………10 4. High Throughput 16S rDNA Gene Amplicon Sequencing and Analysis ……….….11 5. Microbial Cultivation and Identification ……….………………………….……….12 6. Medium for Urinary Microbial Culture ……….………….………………………...12 7. Statistical Analysis ……….……….………….………….…………………….…...13 RESULTS ……………….………….……………….………….………….………….14 1. Individualized Urinary Microbial Variations in PCa Patients. ………….…………..14 2. Similar Urinary Microbiota Composition Were Observed in Different PSA and PHI Groups. …………….…………….………….………….…………….…………….15 3. Pseudomonas and Carnobacterium spp. Showed Positive Correlation and Phylum Proteobacteria, Actinobacteria Bacteria Showed Negative Correlation with High and Intermediate Risk PCa. ……….………….……….………….………….………….18 4. Staphylococcus spp. That Higher in AS Patients Were Also Dominant in Urine Sample of Patients After the Surgery. ……….……………….……….….…………20 5. Genitourinary Microbiota Preserved by Culture Dependent Method. …….….…….20 DISCUSSION ………………………….……………………………………………...22 TABLES AND FIGURES ……………..………………………………………...……26 Table 1. Clinical-pathological Characteristics of NTUH Cohort of PCa Patients. …...…26 Table 2. Culture conditions and mediums. …...………….…………………….…..……27 Table 3. Total Live Strains Cultured from Urine Samples. ………….…….…….………28 Figure 1. Urine Microbial Alpha-Diversity boxplot between Higher and Lower PSA Patients. …….………………….………….………….………….………...…….……. 29 Figure 2. Urine Microbial Alpha-Diversity boxplot between Higher and Lower PHI Patients. …….………….……….………….………….………….……………..….…..30 Figure 3. Urine Microbial Alpha-Diversity boxplot between High and Intermediate Risk and AS Patients. …………..…….………….………………….………….…….………31 Figure 4. Urine Microbial Alpha-Diversity boxplot between Intermediate Risk and AS Patients. ….………….………………….……….………….………….………….........32 Figure 5. Urine Microbial Alpha-Diversity boxplot between High Risk and intermediate risk Patients. ……….………….……….………….………….….…….…….………....33 Figure 6. Urine Microbial Alpha-Diversity boxplot between High Risk and AS (Low risk) Patients. …………………………………..……….………….………….….……….…34 Figure 7. Urine Microbial Alpha-Diversity Boxplot between Before-surgery and Post-surgery. ………….…………….……….………….………….…………………...……35 Figure 8. Principal coordinate analysis (PCoA) using Bray-Curtis metric distances of Urine Microbial Beta-Diversity. ….………….………………………………..…..……36 Figure9. PCoA using Bray-Curtis metric distances of Urine Microbial Beta Diversity. ..37 Figure 10. PCoA using Bray-Curtis metric distances of Urine Microbial Beta Diversity. …..……………………..……….……….……….………….……………… 38 Figure 11. Bacterial average relative abundance in Low PSA (<10) and High PSA (>10). ..………………..………………..………………..…………………...…………39 Figure 12. Bacterial average relative abundance in Lower PHI (35<, <55) and Higher PHI (>55). ..………………..………………..………………..………………..……….……40 Figure 13. Heat tree presenting the relative abundance difference between groups in urinary microbiome of Low PSA (<10) and High PSA (>10) patients. ..………………..41 Figure 14. Heat tree presenting the relative abundance difference between groups in urinary microbiome of lower PHI (35<, <55) and higher PHI (>55) patients. ..………...42 Figure 15. LEfSe analysis for biomarker discovery in urinary microbiome between lower PHI (35<, <55) and higher PHI (>55) patients. ..………………..………………..……..43 Figure 16. Bacterial average relative abundance in High and Intermediate risk vs. AS patients. …………….………………..………………..………………..………………44 Figure 17. Bacterial average relative abundance in Intermediate risk vs. AS patients. ….45 Figure 18. Bacterial average relative abundance in high risk vs. AS patients. …………..46 Figure 19. Heat tree presenting the relative abundance difference between groups in urinary microbiome of AS vs. High and Intermediate risk patients. …………………….47 Figure 20. Heat tree presenting the relative abundance difference between groups in urinary microbiome of AS vs. Intermediate risk patients. ………………………………48 Figure 21. Heat tree presenting the relative abundance difference between groups in urinary microbiome of AS vs. High risk patients. ………………………………………49 Figure 22. LEfSe analysis for biomarker discovery in urinary microbiome between different risk groups. …………………………………………………………………...51 Figure 23. Bacterial average relative abundance in before-surgery and post-surgery. ….52 Figure 24. Heat tree presenting the relative abundance difference between groups in urinary microbiome of before-surgery vs. post-surgery. ………………………………..53 Figure 25. Rarefaction measure between before-surgery (red), surgery (blue) and post- surgery (orange) groups. ………………………………………………………….54 REFERENCES ………………………………………………………………………..55" | |
| dc.language.iso | en | |
| dc.subject | 生殖泌尿道健康 | zh_TW |
| dc.subject | 微生物培養 | zh_TW |
| dc.subject | 攝護腺癌 | zh_TW |
| dc.subject | 生物標記 | zh_TW |
| dc.subject | 微生物相 | zh_TW |
| dc.subject | Culturomics | en |
| dc.subject | Microbiota | en |
| dc.subject | Prostate Cancer | en |
| dc.subject | Biomarkers | en |
| dc.subject | Male GU Health | en |
| dc.title | 探勘泌尿道中與攝護腺癌及男性生殖泌尿道健康相關之潛在微生物標記之體學研究 | zh_TW |
| dc.title | Biomarker Profiling of the Urinal Microbiota Core Components for Prostate Healthcare | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 倪衍玄(Hsin-Tsai Liu),黃昭淵(Chih-Yang Tseng) | |
| dc.subject.keyword | 微生物相,生物標記,攝護腺癌,生殖泌尿道健康,微生物培養, | zh_TW |
| dc.subject.keyword | Microbiota,Prostate Cancer,Biomarkers,Male GU Health,Culturomics, | en |
| dc.relation.page | 57 | |
| dc.identifier.doi | 10.6342/NTU202101733 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2021-07-27 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| dc.date.embargo-lift | 2022-07-31 | - |
| 顯示於系所單位： | 微生物學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2607202100065600.pdf 未授權公開取用 | 4.59 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。